EGFR and non-small cell lung carcinoma: Activating mutations of epidermal growth factor receptor (EGFR) contributes to the progression of NSCLC and small-molecule inhibitors targeting EGFR (tyrosine kinase inhibitor, TKI), including the first- and second-generation EGFR-TKIs such as gefitinib, erlotinib, have demonstrated dramatic efficacy in NSCLC patients with EGFR-activating mutations [2].